Biogen

News

Roche takes on pricey rivals as FDA approves SMA drug

Roche is hoping to undercut hugely expensive rivals after the FDA approved its oral spinal muscular atrophy (SMA) drug Evrysdi (risdiplam).

News

Biogen's shares surge again as FDA hurries Alzheimer's drug ...

Biogen’s Alzheimer’s drug aducanumab could be on the market in the next few months after the FDA accepted a clinical trial dossier and granted a fast Priority Review.

News

Biogen signs $2.1 billion Parkinson's disease deal with Dena...

Biogen has bought a licence to co-develop and co-market potential Parkinson’s disease drugs with US biotech Denali, in a deal worth more than $2.1 billion.

News

Biogen plans trial of Spinraza in patients not responding to...

Biogen is planning to trial its Spinraza spinal muscular atrophy (SMA) drug in patients who have not responded properly to Novartis' gene therapy Zolgensma, combining the two ultra-expensiv

News

Closeup of X-ray photography of human brain

Biogen and Eisai trial drug in asymptomatic Alzheimer's dise...

Biogen and Eisai have begun a new phase 3 study testing an Alzheimer’s antibody drug aimed at patients without symptoms but with elevated levels of amyloid in their brains, the protein aggr

News

Biogen shares pop as it completes filing for Alzheimer's dru...

Biogen’s share price was up sharply on Wednesday after the big pharma completed its filing of its Alzheimer’s Disease (AD) drug aducanumab with the FDA.

Roche takes on pricey rivals as FDA approves SMA drug

Biogen's shares surge again as FDA hurries Alzheimer's drug ...

Biogen signs $2.1 billion Parkinson's disease deal with Dena...

Biogen plans trial of Spinraza in patients not responding to...

Biogen and Eisai trial drug in asymptomatic Alzheimer's dise...

Biogen shares pop as it completes filing for Alzheimer's dru...

Ambrosia's sweet $100m round, and other biofinancings

Using AI-driven synthetic personas to take your insights fur...

Biogen

Editor's Picks